Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO) Sees Significant Increase in Short Interest

Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO) was the recipient of a significant increase in short interest during the month of December. As of December 31st, there was short interest totaling 5,385 shares, an increase of 145.8% from the December 15th total of 2,191 shares. Approximately 0.3% of the company’s shares are sold short. Based on an average daily trading volume, of 31,578 shares, the days-to-cover ratio is currently 0.2 days. Based on an average daily trading volume, of 31,578 shares, the days-to-cover ratio is currently 0.2 days. Approximately 0.3% of the company’s shares are sold short.

Hedge Funds Weigh In On Cardio Diagnostics

An institutional investor recently bought a new position in Cardio Diagnostics stock. Citadel Advisors LLC purchased a new stake in shares of Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 19,520 shares of the company’s stock, valued at approximately $79,000. Citadel Advisors LLC owned 1.07% of Cardio Diagnostics at the end of the most recent quarter. 8.06% of the stock is currently owned by hedge funds and other institutional investors.

Cardio Diagnostics Price Performance

CDIO stock traded up $0.09 during mid-day trading on Friday, reaching $1.85. The company had a trading volume of 55,919 shares, compared to its average volume of 2,027,802. The company has a market capitalization of $3.38 million, a PE ratio of -0.49 and a beta of 2.94. The firm has a 50 day moving average of $3.03 and a 200 day moving average of $3.67. Cardio Diagnostics has a 12 month low of $1.64 and a 12 month high of $21.15.

Cardio Diagnostics (NASDAQ:CDIO) last posted its quarterly earnings results on Wednesday, November 12th. The company reported ($0.98) earnings per share for the quarter, beating the consensus estimate of ($1.80) by $0.82. Cardio Diagnostics had a negative net margin of 39,674.18% and a negative return on equity of 67.51%. The firm had revenue of $0.00 million during the quarter, compared to the consensus estimate of $0.15 million. Analysts anticipate that Cardio Diagnostics will post -0.55 EPS for the current year.

Wall Street Analyst Weigh In

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of Cardio Diagnostics in a report on Monday, December 29th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock currently has an average rating of “Sell”.

Cardio Diagnostics Company Profile

Cardio Diagnostics Holdings, Inc develops and commercializes epigenetics-based clinical tests for cardiovascular disease. It offers Epi+Gen CHD, a three-year symptomatic coronary heart disease (CHD) risk assessment test targeting CHD events, including heart attacks; and PrecisionCHD, an integrated epigenetic-genetic blood test for the early detection of coronary heart disease. Cardio Diagnostics Holdings, Inc was founded in 2017 and is headquartered in Chicago, Illinois.